ERBB2 and breast carcinoma: Currently, novel HER2-directed antibody-drug conjugate (ADC) agents, such as trastuzumab deruxtecan, not only show antitumor activity in classical HER2-positive breast cancer but also in HER2-low tumors, defined as tumors with an IHC score of 1+/2+ and negative ISH results [3–5].